HKSE - Delayed Quote HKD

Brii Biosciences Limited (2137.HK)

1.160 +0.070 (+6.42%)
At close: April 26 at 4:08 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
617.000
617.000
51,626.000
--
--
Operating Expense
545,349.000
545,349.000
565,814.000
642,614.000
911,884.000
Operating Income
-544,732.000
-544,732.000
-514,188.000
-642,614.000
-911,884.000
Net Non Operating Interest Income Expense
107,529.000
107,529.000
36,353.000
5,315.000
739.000
Pretax Income
-184,370.000
-184,370.000
-489,781.000
-4,191,084.000
-1,283,510.000
Net Income Common Stockholders
-174,829.000
-174,829.000
-484,312.000
-4,163,849.000
-1,189,600.000
Diluted NI Available to Com Stockholders
-174,829.000
-174,829.000
-484,312.000
-4,163,849.000
-1,189,600.000
Basic EPS
-0.24
--
-0.67
-9.48
-1.68
Diluted EPS
-0.24
--
-0.67
-9.48
-1.68
Basic Average Shares
728,100.000
--
723,478.000
439,047.000
706,200.926
Diluted Average Shares
728,100.000
--
723,478.000
439,047.000
706,200.926
Total Expenses
545,349.000
545,349.000
565,814.000
642,614.000
911,884.000
Net Income from Continuing & Discontinued Operation
-174,829.000
-174,829.000
-484,312.000
-4,163,849.000
-1,189,600.000
Normalized Income
-437,454.000
-437,454.000
-515,998.000
-4,208,644.000
-1,174,581.000
Interest Income
108,023.000
108,023.000
37,204.000
6,490.000
2,407.000
Interest Expense
494.000
494.000
851.000
1,175.000
1,668.000
Net Interest Income
107,529.000
107,529.000
36,353.000
5,315.000
739.000
EBIT
-183,876.000
-183,876.000
-488,930.000
-4,189,909.000
-1,281,842.000
EBITDA
-168,202.000
-168,202.000
-471,898.000
-4,172,647.000
-1,267,633.000
Reconciled Depreciation
15,674.000
15,674.000
17,032.000
17,262.000
14,209.000
Net Income from Continuing Operation Net Minority Interest
-174,829.000
-174,829.000
-484,312.000
-4,163,849.000
-1,189,600.000
Total Unusual Items Excluding Goodwill
262,625.000
262,625.000
31,686.000
44,795.000
-15,019.000
Total Unusual Items
262,625.000
262,625.000
31,686.000
44,795.000
-15,019.000
Normalized EBITDA
-430,827.000
-430,827.000
-503,584.000
-4,217,442.000
-1,252,614.000
12/31/2020 - 7/13/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1873.HK Viva Biotech Holdings
0.560
0.00%
 
2197.HK Clover Biopharmaceuticals, Ltd.
0.360
+9.09%
 
1877.HK Shanghai Junshi Biosciences Co., Ltd.
10.740
+4.88%
 
9939.HK Kintor Pharmaceutical Limited
0.960
+2.13%
 
6160.HK BeiGene, Ltd.
91.950
+2.17%
 
2179.HK Jiangsu Recbio Technology Co., Ltd.
9.130
0.00%
 
AVXT AVAX Technologies, Inc.
0.0001
0.00%
 
002252.SZ Shanghai RAAS Blood Products Co., Ltd.
7.19
-0.96%
 
1477.HK Ocumension Therapeutics
6.470
+7.83%
 
41X.F Ardelyx, Inc.
5.83
-3.60%